Log In
BCIQ
Print this Print this
 

Anandron, Nilandron, nilutamide

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionOral testosterone blocker
Molecular Target Androgen receptor
Mechanism of ActionAndrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation
PartnerConcordia International Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,200.0M

$1,200.0M

0


 Deals Details
Get a free BioCentury trial today